SIGA Technologies AI Stock Analysis
Want to see SIGA full AI Analyst Report?
SIGA Technologies (SIGA) AI Stock Analysis
SIGA Technologies
(NASDAQ:SIGA)
The score is held back primarily by weakened near-term fundamentals in the TTM data (large loss and negative free cash flow) and bearish technical trend signals. These are partially offset by a strong balance sheet and a generally constructive earnings call highlighting new contracted demand and ongoing international opportunities, but valuation is a significant negative given the very high P/E and no dividend yield.
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $225.62M
- Dividend Yield
- ―
- Average Volume (3M)
- 618.17K
- Price to Earnings (P/E)
- 490.6
- Beta (1Y)
- 1.27
- Revenue Growth
- -69.60%
- EPS Growth
- -99.10%
- Country
- US
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
SIGA Technologies Business Overview & Revenue Model
Company Description
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human...
How the Company Makes Money
SIGA makes money primarily by selling TPOXX (tecovirimat) under government procurement and stockpiling programs for biodefense and emergency preparedness. A significant portion of revenue is generated through contracts and purchase orders from govern...
SIGA Technologies Earnings Call Summary
The call was generally positive, supported by completion of the BARDA 19C contract, a new Canadian agreement worth up to approximately $15 million, additional international discussions, broad TPOXX approvals and stockpiling, nine-month profitability, and a cash balance of approximately $116 million with no debt. Offsetting concerns included uncertain timing for a new U.S. procurement award, the PEP filing delay to 2028, no third-quarter product sales, third-quarter losses, and timing challenges in Europe.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
SIGA expects results from the phase I study of its pediatric formulation by year end, and expects to file its supplemental NDA for the PEP program in 2028. Under the CDND contract, valued up to approximately $15 million over the next five years, firm commitments are about $9 million over the first three years, plus up to $6 million in options; deliveries are expected to start in 2027, with an equal number of oral TPOXX courses delivered in each of the first three fiscal years, while options can be ordered and delivered at any point in time during the five-year contract. SIGA continues to believe that a new U.S. procurement contract will be awarded, although the timing of an award remains uncertain, and does not currently expect the midterm results to have any material impact on the nature or trajectory of the process beyond the typical transition period that follows any election.
SIGA Technologies Financial Statement Overview
Summary
Annual financials show a historically profitable, low-debt profile with strong margins, but the most recent TTM picture is a major concern: an extreme reported net loss and a swing to negative operating/free cash flow materially weaken confidence in near-term earnings quality and cash generation. Balance sheet strength helps, but current profitability and cash flow instability keep this score mid-range.
Income Statement
58NeutralBalance Sheet
80PositiveCash Flow
44Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.36M | 94.60M | 138.72M | 139.92M | 110.78M | 133.67M |
| Gross Profit | 28.29M | 64.87M | 107.43M | 122.09M | 100.34M | 117.07M |
| EBITDA | -2.17M | 30.96M | 76.61M | 88.31M | 44.65M | 89.83M |
| Net Income | 716.12K | 23.30M | 59.21M | 68.07M | 33.90M | 69.45M |
Balance Sheet | ||||||
| Total Assets | 172.65M | 219.47M | 244.34M | 254.35M | 195.04M | 214.73M |
| Cash, Cash Equivalents and Short-Term Investments | 116.38M | 154.97M | 155.40M | 150.15M | 98.79M | 103.14M |
| Total Debt | 274.61K | 595.17K | 546.82K | 564.01K | 528.17K | 466.83K |
| Total Liabilities | 9.39M | 20.65M | 28.53M | 57.49M | 24.88M | 40.41M |
| Stockholders Equity | 163.25M | 198.82M | 215.80M | 196.86M | 170.16M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | -11.57M | 43.12M | 48.72M | 94.78M | 41.61M | 11.44M |
| Operating Cash Flow | -11.53M | 43.47M | 48.76M | 94.80M | 41.61M | 11.49M |
| Investing Cash Flow | -40.54K | -355.01K | -42.45K | -21.69K | 0 | -50.62K |
| Financing Cash Flow | -44.00M | -43.55M | -43.46M | -43.42M | -45.96M | -26.20M |
SIGA Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Neutral. The current price of 3.14 is above the 20-day moving average (MA) of 3.14, below the 50-day MA of 3.19, and below the 200-day MA of 4.08, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.36 is Neutral, neither overbought nor oversold. The STOCH value of 52.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksSIGA Technologies Peers Comparison
Overall Rating
RDY67Neutral
VTRS58Neutral
CPHI56Neutral- SIGA54Neutral
PRGO52Neutral
EBS45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| RDY | 67Neutral | $12.32B | 40.98 | 7.37% | 0.56% | -10.52% | -55.45% |
| VTRS | 58Neutral | $23.90B | -39.73 | -4.24% | 2.28% | 4.80% | 82.97% |
| CPHI | 56Neutral | $23.71M | -0.54 | -17.14% | ― | -10.97% | 71.83% |
| SIGA | 54Neutral | $224.91M | 490.62 | 0.42% | ― | -69.60% | -99.10% |
| PRGO | 52Neutral | $2.34B | -1.30 | -68.13% | 7.01% | -4.45% | -3289.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| EBS | 45Neutral | $311.06M | -1.20 | -61.33% | ― | -17.72% | -456.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SIGA | Siga Technologies | 3.14 | -2.24 | -41.61% | |
| CPHI | China Pharma | 0.54 | -0.98 | -64.28% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.84 | 1.05 | 7.58% | |
| EBS | Emergent Biosolutions | 6.04 | -4.28 | -41.47% | |
| VTRS | Viatris, Inc. | 21.06 | 10.52 | 99.89% | |
| PRGO | Perrigo Company | 16.55 | 3.78 | 29.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026